Immunogenicity, Reactogenicity and Safety of the Trivalent Influenza Subunit Vaccine Influvac for the Season 2009/2010. An Open-Label, Baseline-Controlled Multi-Center Study in Two Groups: Adult Subjects and Elderly Subjects.
Phase of Trial: Phase III
Latest Information Update: 01 Feb 2016
At a glance
- Drugs Influenza virus vaccine (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Solvay Pharmaceuticals
- 15 Mar 2012 This trial is recruting in Germany as reported by European Clinical Trials Database.
- 15 Mar 2012 Actual initiation date changed from Jun 2009 to May 2009 as reported by European Clinical Trials Database.
- 09 Oct 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.